Stockreport

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing ExpertiseFuchs Endothelial Corneal Dystrophy (FECD) Afflicts More [Read more]